BioPrime Antibodies - CD138A-5: CD138, Plasma Cells, Syndecan-1

Products:

AGE

BioPrime Antibodies

BioPrime Staining Reagents

Proteins and Peptides

VECTOR Reagents

Products> BioPrime Antibodies

CD138A-5: CD138, Plasma Cells, Syndecan-1

Print page

place in shopping cart

Price: 120 € / 5 ml

Monoclonal Antibodies

Origin:	Mouse

Isotype:	IgG1

Clone:	B-A38

Format:	Ready to use antibody solution

Quantity:	5 ml

Working concentration:	neat

Presentation:	Antibody solution in stabilizing phosphate buffer pH 7.3. Contains BSA and 0.09 % sodium azide**. The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.

Immunogen:	U266 cell line

Specificity:	Human CD138, Syndecan 1

Species Specificity:	Human

General Information:	Syndecan 1, CD138, is a heparan-rich glycoprotein (MW 200 kDa), which is expressed on the cell membrane of plasma cells. CD138 functions as a receptor for extracellular matrix proteins like collagen, fibronectin and thrombospondin.

Special properties:	The antibody B-A38 stains all plasma cells and all plasma cell lines, which have been tested so far. No other leukocytes are stained in peripheral blood or bone marrow. However, some ALL cell lines express CD138 weekly, and some epithelia and endothelia may be stained in immunohistochemistry.

Positive control:	Tonsil

Pre-treatment:	No protease necessary for IHC, but heat pre-treatment with citrate buffer (Art. No. DE000) or EDTA buffer pH 9 (Art. No. DE006) may enhance staining intensity on formalin fixed, paraffin embedded material.

Applications:	IHC (C, P)

Incubation time:	IHC(P) 60 min at RT or 2-8°C over night

Secondary reagents:	We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005), if higher sensitivity is required VECTASTAIN Elite ABC (Art. No. PK-6102) or ABC AP (Art. No. AK-5002) systems are applicable.

Storage:	2-8°C

References:
1. Borset M., et al. (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haem. 85; 446 ff.

2. Wijdenes J., et al. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognises Syndecan-1. Br. J. Haem. 94; 318-323.

3. Inki. P. and Jalkanen M. (1996) The role of syndecan-1 in malignancies. Ann. Med. 28(1); 63-67.

4. Anttonen A., et al. (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Brit J. Cancer 79; 558-564.

5. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G,Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J,Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 110(6):2041-2048.

Notes:
BIOLOGO antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.

** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!